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ÖZET
Amaç:  Diyabetin  son  dönem  böbrek  yetmezliği  riskini 
artırdığı  bildirilmiştir.  Diyabetik  nefropatinin  ilerlemesini 
önlemede yeni yaklaşımlar gereklidir, çünkü iyi metabolik 
kontrole rağmen diyabetik hastalar ilerleyici böbrek hasa-
rı gösterir. Bu çalışmanın amacı düşük molekül ağırlıklı 
heparin ve vitamin E’nin diyabetik nefropatili hastalardaki 
rolünü araştırmaktır. 
Gereç ve yöntem: Klinik olarak kanıtlanmış, yeterli gli-
semik kontolu ve kan basıncı kontrolu insulin, oral hipog-
lisemikler ve kan basıncı düşürücüler (ACE inhibitörü ve 
ARB’ler hariç) ile sağlanmış, diyabetik nefropatisi olan 25 
erişkin hasta çalışmaya dahil edildi. Çalışmanın başlangı-
cında hastalara DMAH (3200 Ünite, subkutan günde bir 
kez) bir ay verildi ve takiben bir ay beklenip daha sonra üç 
ay süreyle E vitamini (Günde bir kez 200 mg) verildi.
Bulgular:  Hastaların  bazal  mikroalbuminüri  değerleri, 
41.0 ile 290.0 mg/24 st arasında değişiyordu. Bir aylık 
DMAH bu değeri 133.0 ± 74.4 mg/24 st’den 93.3 ± 62.1 
mg/24 st’e düşürdü (p <0.001). Üç ay süreli vitamin E 
suplementasyonu mikroalbuminüri değerinde istatistiksel 
olarak anlamlı bir değişiklik yapmadı (Sırasıyla, 95.2 ± 
13.0 mg/24 st ve 94.2 ± 12.9 mg/24 st, p>0.05). Mikro-
albuminüri değerleri çalışma süresi olan 5 ayın sonunda 
başlangıçtaki bazal değerlere dönmemiş olduğu görüldü.
Sonuç: Çalışmamızın sonuçlarına göre, standart tedavi 
rejiminin bir parçası olmasa bile, DMAH ve takiben vita-
min E tedavisinin diabetik nefropati beklenen dönemde 
dikkate alınması gerekir.
Anahtar kelimeler: Düşük molekül ağırlıklı heparin, vita-
min E, diyabetik nefropati, böbrek fonksiyonları
ABSTRACT
Objectives: Diabetes has been reported to increase the 
risk of end stage renal disease. To prevent the progres-
sion of diabetic nephropathy (DN) search for newer ap-
proaches is warranted as diabetic patients despite good 
metabolic control show progressive renal damage. The 
aim of this study was to investigate the role of low molecu-
lar heparin (LWMH) and vitamin E in patients with diabetic 
nephropathy.
Materials  and  methods:  Twenty  five  clinically  proved 
adult  cases  of  DN  with  adequate  glycemic  and  blood 
pressure control achieved with insulin or oral hypoglyce-
mics and anti hypertensive agents (excluding ACE inhibi-
tors and ARBs) were included. At the start of the study, 
patients were put on LWMH (3200 IU S/C once daily) for 
one month and thereafter a washout period of one month 
was given, following which patients received anti-oxidant 
vitamin-E (200mg, once daily) for three months.
Results: Patients at the baseline have microalbuminuria 
levels ranging for 41.0 to 290.0 mg/ 24hr. One month of 
LMWH reduced it from 133.0±74.4 to 93.3±62.1 mg/24hr 
(p<0.001). Vitamin E supplementation for 3 months did 
not bring any statistically significant change in the val-
ues of microalbuminuria which varied from 95.2±13.0 to 
94.2±12.9 mg/24hr (p>0.05). The microalbuminuria levels 
did not revert back to the baseline till the end of the study 
(5 months).
Conclusion: Our results indicated that, though not a part 
of standard regime, LMWH treatment followed by vitamin 
E supplementation needs to be considered in the incipient 
stage of DN.
Key words: Low molecular weight heparin, vitamin E, 
diabetic nephropathy, renal functions
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INTRODUCTION
The development of sustained proteinuria is the ma-
jor criterion for the diagnosis of diabetic nephropa-
thy (DN). The albuminuria in the range of 30 to 300 
mg/day is known as microalbuminuria. Persistent 
microalbuminuria is considered to indicate high risk 
for ultimate progression to renal failure.1
The search for newer approaches for the pre-
vention and treatment of DN is warranted because 
even diabetic patients responding to ACEI therapy 
and metabolic control show progressive renal dam-
age and eventually ESRD.2 In view of these changes 
amongst the number of drugs being currently in-
vestigated, glycosaminoglycans (GAGs) appeared 
particularly interesting because they target the gen-
eralized endothelial dysfunction and the metabolic 
defect in the matrix and basement membrane syn-
thesis,  which  are  responsible  for  DN.3,4  Heparin, 
Low molecular weight heparin (LMWH) and other 
GAGs have been reported to prevent diabetes-in-
duced albuminuria, loss of anionic sites and thick-
ening of the GBM and glomerulosclerosis.5-14
Oxidative  stress  has  also  been  implicated  as 
an important causative factor in the progression of 
DN.15,16 Treatment with antioxidants such as Vita-
min E may help in ameliorating the effects of oxida-
tive stress in the progression of DN.
This prospective study was planned to evalu-
ate the efficacy of LMWH in patients with DN. A 
treatment of vitamin E following heparin was cho-
sen to cover the oxidative stress. The study becomes 
all the more important in the light of recent studies 
which have shown that a delay in controlling dia-
betes leads to certain nephropathic changes which 
may not be easily reversed completely.17
MATERIALS AND METHODS
The study was conducted at Pt B.D.Sharma Post 
Graduate  Institute  of  Medical  Sciences,  Rohtak. 
Twenty five clinically proved adult cases of type II 
diabetes mellitus with diabetic nephropathy (DN) at-
tending medicine OPD were taken up for the study. 
It  was  an  open  and  prospective  study  conducted 
over a period of five months. All the patients were 
detailed about the study and pre-informed written 
consent was obtained before the study. Before sub-
jecting the patients to study adequate glycemic and 
blood pressure control was achieved with Insulin 
or Oral hypoglycemic and anti hypertensive agents 
excluding  ACE  inhibitors  and  ARBs.  The  study 
period was divided into three parts. At the begin-
ning of study patients were put on low molecular 
weight heparin {Injection Fluxum (Parnaparin so-
dium) 3200 IU S/C once daily} for a period of one 
month. Thereafter a washout period of one month 
was given, following which patients were put on 
anti-oxidant therapy (vitamin-E 200 mg) once daily 
for 3 months.
Patients  of  diabetes  mellitus  with  stage  III 
diabetic nephropathy were included in the study1. 
Patients excluded from the study were those with 
unstable  angina,  uncontrolled  hypertension,  heart 
failure, cirrhosis and those suffering from any other 
renal disease. Patients with bleeding disorder and 
malignancy (central bleeding), pregnant or lactating 
mothers, women of child bearing age, who had tak-
en heparin for any reasons in last 3 months, or were 
on aspirin and other anti platelet drugs or had hyper-
sensitivity to heparin and related products were also 
excluded from the study.
All  the  patients  were  subjected  to  investiga-
tions like complete haemogram, various renal bio-
chemical parameters, urine complete examination, 
24 hr urine for protein and creatinine and creatinine 
clearance was estimated. Special investigations like 
microalbuminuria  by  spectrophotometry,  reduced 
glutathione levels and malonialdehyde levels were 
also estimated.
All these tests were done at the start (basal), 
after one month of heparin treatment, after washout 
period (two months), and following three months of 
vitamin E therapy.
The data obtained was subjected to standard 
statistical analysis. For comparison paired samples 
‘t’ test was applied. P values were calculated and 
p<0.05  was  considered  to  be  statistically  signifi-
cant.
RESULTS
Totally  25  patients  enrolled  in  the  present  study 
there were 12 males and 13 females. The age profile 
of patients showed that a maximum of 40% patients 
were in the age group of 40-49 which was followed 
by 32% patients above the age of 50 and the rest of 
32% were below 39 and above 20 years. The blood 
sugar of the patients remained controlled through-
out the study.H. K. Aggarwal et al. Diabetic nephropathy 131
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Patients at baseline had microalbuminuria lev-
els ranging from 41.0 to 290.0 mg/24hr. Microal-
buminuria decreased significantly from a baseline 
value of 133 ± 14.9 to 93.3 ± 12.4 by 1 month of 
LMWH (p< 0.001). Following one month of wash-
out period the levels increased slightly from 93.3 ± 
12.4 to 95.2 ± 13.0 but it was not significant statisti-
cally (p>0.05). But the fall was significant when the 
wash out period was compared with the base line 
showing a decrease from 133 ± 14.9 to 95.2 ± 13.02 
(p<0.001) [Table 1]. Further, Vitamin E supplemen-
tation for 3 months did not bring any statistically 
significant change in the values of microalbuminu-
ria which varied from 95.2 ± 13.0 to 94.2 ± 12.9 
(p>0.05). However on comparison with the baseline 
values, the levels continued to remain lower ranging 
from 133 ± 14.9 to 94.2 ± 12.9 (p<0.001) [Table 2]. 
Thus the earlier effects of LMWH treatment contin-
ued to persist up to 4 months (1 month washout + 3 
months vitamin E).
Table 1. The effect of low molecular weight heparin on microalbuminuria levels
Parameters
Baseline
Mean ± SD I
LMWH treatment
(1 month) Mean ± SD II
Washout period
(1 month) Mean ± SD III
P value
I vs II
P value
II vs III
P value
III vs I
Microalbuminuria
(mg/24hr) 133 ± 14.88 93.3 ± 12.42 95.2 ± 13.02 P<0.001 P>0.05 P<0.001
Table 2. The effect of vitamin E on microalbuminuria levels
Parameters
Baseline value
(Mean ± SD) I
Before vitamin E
(Mean ± SD) II
After Vitamin E
(3 months) (Mean ± SD) III
P value
II vs III
P value
I vs III
Microalbuminuria (mg/24hr) 133 ± 14.88 95.2 ± 13.02 94.2 ± 12.88 P<0.05 P>0.001
Table 3. The effect of low molecular weight heparin and vitamin E on reduced glutathione and malondialdehyde lev-
els
Parameters Baseline ± SD LMWH treatment (1 month)* Washout period (1 month) * After 3 months of Vit E**
GSH (mg%) 10 ± 0.09 10.18 ± 0.10 10.27 ± 0.09 13.32 ± 0.18
MDA (µmol/L) 2.41 ± 0.11 2.39 ± 0.18 2.32 ± 0.10 1.69 ± 0.06
*All the values were not significantly different from the baseline values at p>0.05
**All the values were significantly different from the baseline values at p <0.001
Heparin  did  not  affect  GSH  levels,  which 
showed a variation from 10.11 ± 0.09 to 10.18 ± 
0.10 which was non significant statistically(p>0.05).
Further wash out period also showed no variation 
(p>0.05)  Malonialdehyde  (MDA)  levels  also  re-
mained  unaffected  by  heparin  treatment  indicat-
ing that LMWH had no antioxidant activity (Table 
4).However treatment with vitamin E significantly 
increased the levels of GSH from 10.27 ± 0.09 to 
13.32 ± 0.18 (p<0.001), which was in accordance 
with the antioxidant properties of vitamin E .Simi-
larly malonialdehyde levels also show a highly sig-
nificant reduction from 2.32 ± 0.10 to 1.69 ± 0.06 
(p<0.01) following vitamin E, indicating that vita-
min E had a role in alleviating oxidative stress in 
patients of diabetic nephropathy (Table 3).
DISCUSSION
Microalbuminuria is considered as one of the first 
clinical markers of DN1 and is commonly consid-
ered either hemodynamic in origin due to endothe-
lial dysfunction or biochemical, due to alteration in 
glomerular  basement  membrane  glycosaminogly-
can composition, leading to an abnormal permse-
lectivity4.  The  data  presented  in  Table  1  shows 
that microalbuminuria decreased significantly by 1 
month of LMWH. Our study is in line with Mayrup 
et al who reported a significant decrease (30-35%) 
in microalbuminuria/24 hour UAE after treatment 
with LMW-heparin (2000 anti Xa IU injected sub-
cutaneously) or unfractioned heparin (5000 IU) for 
3 months in type 1 diabetic patients. However, their 
measurements after 3 months could not ascertain H. K. Aggarwal et al. Diabetic nephropathy 132
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that  the  progression  in  albuminuria  could  be  de-
layed by LMWH treatment or not.6 In our study on 
the other hand, it was observed that the microalbu-
minuria levels continued to remain below the base-
line levels till the end of the study. Studies using 
different GAGs and their combinations have also 
reported a generalized reduction in microalbuminu-
ria in diabetic patients.6-14
The only report from the literature which shows 
that  heparin  does  not  affect  microalbuminuria  in 
type 2 diabetic patients used Tinzaparin, a low mo-
lecular weight heparin. This was because Tinzaparin 
had an average molecular weight of 6500 Daltons 
versus 4500 Daltons for enoxiparin, and moreover 
has an anti-factor Xa to anti-factor IIa activity ra-
tio of 1.5:2.5 versus 3.3:5.3. Thus, in molar terms, 
type 2 diabetic patients received 30% less LMWH. 
Furthermore, differences in molecular weight and 
anti-X and anti-II activity may be indirect hallmarks 
of different renoprotective potency of the heparin 
formulation used.18
Based upon epidemiological data, the genetic 
differences in the enzymes involved in the sulphation 
of GAG side-chains of heparan sulphate proteogly-
cans are of crucial importance in the pathogenesis of 
DN and the recent in-vitro and in-vivo studies have 
put light on the role of HS-GAG in the pathogenesis 
of DN.19 In addition, various experimental and hu-
man studies have shown heparin to reduce proteinu-
ria and prevent thickening of glomerular basement 
membrane glomerular and anionic charge in diabetic 
nephropathy.6-14 Several early studies suggested that 
glomerular epithelial and endothelial cells produce 
a heparin like substance that inhibits the mesangial 
cell growth glomerular injury; it is conceivable that 
the production of this substance is decreased allow-
ing cell proliferation and matrix accumulation as 
observed in streptozotocin diabetic animals and in 
the renal ablation model.20 Exogenous heparin may 
replace the endogenously synthesized thus lowering 
microalbuminuria in diabetic patients as observed 
in the present study.
It was further observed in the present study that 
vitamin E supplementation 200 mg/day for three 
months  did  not  cause  any  statistically  significant 
change in the values of microalbuminuria. Thus the 
earlier effects of LMWH treatment continued to per-
sist for upto 4 months (1 month washout + 3 months 
vitamin E). The reduction in microalbuminuria after 
vitamin E therapy has been reported by Hirnerova 
et al who after using a very high dose of vitamin E 
(1200 IU/day for 4 months) observed that microal-
buminuria was significantly reduced in the patients 
of DN after 2 and 4 months of therapy.21 Yokoyama 
et al using a lower dose of 600 mg/day vitamin E 
found Urinary albumin excretion to decrease sig-
nificantly by 10.8% in patients with good glycemic 
control (HbA1c < 7.0%).22 However, Nakamura et 
al did not find any change in microalbuminuria in 
type 2 diabetic patients given vitamin E at 300 mg/
day.23 In the present study microalbuminuria levels 
continued to remain lower than the baseline till the 
end of the study (5 months), it is difficult to ascertain 
whether this effect on microalbuminuria levels was 
a carry forward effect of heparin for up to 5 months 
or was it the effect of vitamin E supplementation. 
Elevated extra and intra cellular glucose concentra-
tion results in increased formation of reactive oxy-
gen species (ROS) with concomitant increase in in-
tracellular AGE formation. These AGE s especially 
N-carboxymethyl lysine, pentosidine accumulate in 
expanded mesangial and nodular lesions of diabetic 
nephropathy. ROS up regulate transforming factor 
–beta1, plasminogen activator inhibitor-1, and ex-
tra cellular matrix proteins by glomerular mesangial 
cells, thus leading to mesangial expansion.24 Vitamin 
E enhances plasma and red blood cell level of GSH, 
hence causing significant improvement in markers 
of oxidative stress resulting in prevention of micro 
and macro vascular complication of DM. Vitamin 
E supplementation has been shown to decrease mi-
croalbuminuria in patients of DN and also known to 
ameliorate renal damage; hence the observed main-
tenance of microalbuminuria after the cessation of 
LMWH treatment could be due to the role of vita-
min E supplementation in delaying the progression 
of DN. The studies conducted so far on heparin8 and 
other GAGs8-16 do not support the idea that the ef-
fect on microalbuminuria could be a carry forward 
effect of LMWH because they have not observed 
the persistence of the effects of heparin/GAGs over 
longer period of time. Vitamin E supplementation, 
at a low dose of 200 mg /day might have helped in 
sustaining the effects of LMWH and in maintain-
ing microalbuminuria levels lower than the baseline 
levels till the study was terminated.
The  present  study  has  several  limitations, 
which include limited number of patients and small 
duration of treatment. Further all the patients were H. K. Aggarwal et al. Diabetic nephropathy 133
Dicle Tıp Derg / Dicle Med J Cilt / Vol 38, No 2, 129-133
Indians and there was no control group for compar-
ing placebo verses heparin treatment. Therefore the 
results of present study cannot be generalized to all 
diabetic patients.
Although promising, the studies published thus 
far  have  generally  been  too  short-term  to  clarify 
whether GAG treatment in diabetic patients is ca-
pable of curing DN, instead of simply influencing 
one of its surrogate end points, albuminuria includ-
ing the present one. As far as known this is a first 
study of its kind in India where LMWH treatment 
followed by vitamin E supplementation have been 
used to study their effect on microalbuminuria in 
patients of DN. The results from the study indicate 
that though not a part of standard regime of treat-
ment of DN, LMWH treatment needs to be consid-
ered in the early stage of DN.
However further long term multicentric trials 
are required to determine whether the benefits ob-
served in the present study could be prolonged by 
long term use of LMWH treatment.
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